Neil E. Kay

30.8k total citations · 2 hit papers
493 papers, 17.3k citations indexed

About

Neil E. Kay is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Neil E. Kay has authored 493 papers receiving a total of 17.3k indexed citations (citations by other indexed papers that have themselves been cited), including 411 papers in Genetics, 238 papers in Pathology and Forensic Medicine and 191 papers in Immunology. Recurrent topics in Neil E. Kay's work include Chronic Lymphocytic Leukemia Research (407 papers), Lymphoma Diagnosis and Treatment (221 papers) and Immunodeficiency and Autoimmune Disorders (128 papers). Neil E. Kay is often cited by papers focused on Chronic Lymphocytic Leukemia Research (407 papers), Lymphoma Diagnosis and Treatment (221 papers) and Immunodeficiency and Autoimmune Disorders (128 papers). Neil E. Kay collaborates with scholars based in United States, United Kingdom and Italy. Neil E. Kay's co-authors include Tait D. Shanafelt, Diane F. Jelinek, Timothy G. Call, Clive S. Zent, Susan L. Slager, Michael R. Grever, Nancy D. Bone, KR Rai, Cheson Bd and Stephen J. O’Brien and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Neil E. Kay

473 papers receiving 16.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1996 1.5k citations Neil E. Kay et al. Blood profile →
ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

2004 659 citations Michael J. Keating, Neil E. Kay et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Neil E. Kay	11.3k	8.4k	6.9k	4.3k	3.1k	493	17.3k
Tadeusz Robak	10.0k 0.9×	7.8k 0.9×	5.3k 0.8×	5.3k 1.3×	5.8k 1.8×	712	19.3k
R. Kanti	16.0k 1.4×	11.4k 1.3×	9.0k 1.3×	7.2k 1.7×	2.9k 0.9×	281	23.3k
Maher Albitar	8.2k 0.7×	4.3k 0.5×	3.4k 0.5×	7.5k 1.8×	9.2k 2.9×	342	20.0k
Andrew W. Roberts	4.9k 0.4×	3.2k 0.4×	4.7k 0.7×	7.6k 1.8×	5.5k 1.8×	275	17.4k
Allen P. Kaplan	10.5k 0.9×	4.5k 0.5×	5.1k 0.7×	2.0k 0.5×	3.3k 1.1×	321	18.6k
Anas Younes	5.0k 0.4×	11.6k 1.4×	4.0k 0.6×	6.5k 1.5×	1.8k 0.6×	529	22.1k
Irene M. Ghobrial	4.6k 0.4×	4.1k 0.5×	2.9k 0.4×	8.6k 2.0×	6.5k 2.1×	484	17.1k
Steven T. Rosen	1.9k 0.2×	6.5k 0.8×	3.3k 0.5×	4.5k 1.0×	1.5k 0.5×	423	15.9k
Zeev Estrov	10.5k 0.9×	3.5k 0.4×	3.5k 0.5×	11.7k 2.7×	13.3k 4.2×	669	26.3k
Jordan U. Gutterman	2.9k 0.3×	1.8k 0.2×	4.5k 0.7×	4.8k 1.1×	4.0k 1.3×	312	16.2k

Countries citing papers authored by Neil E. Kay

Since Specialization

Citations

This map shows the geographic impact of Neil E. Kay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil E. Kay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil E. Kay more than expected).

Fields of papers citing papers by Neil E. Kay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil E. Kay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil E. Kay. The network helps show where Neil E. Kay may publish in the future.

Co-authorship network of co-authors of Neil E. Kay

This figure shows the co-authorship network connecting the top 25 collaborators of Neil E. Kay. A scholar is included among the top collaborators of Neil E. Kay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil E. Kay. Neil E. Kay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guo, Qianqian, Yuan Gao, Sutapa Sinha, et al.. (2024). Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia. SHILAP Revista de lepidopterología. 2(1). 100059–100059.

Giacopelli, Brian, Kari G. Rabe, Yue-Zhong Wu, et al.. (2024). Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature. Blood. 143(17). 1752–1757. 2 indexed citations

O’Brien, Daniel R., Erik Jessen, Cecília Bonolo de Campos, et al.. (2024). Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations. Cancers. 16(13). 2450–2450. 2 indexed citations

Kay, Neil E., Sameer A. Parikh, Kari G. Rabe, et al.. (2022). Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma. 64(2). 300–311. 2 indexed citations

Boddicker, Nicholas, Sara J. Achenbach, Sameer A. Parikh, et al.. (2022). Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. Leukemia. 36(5). 1404–1407. 3 indexed citations

Slager, Susan L., Sameer A. Parikh, Sara J. Achenbach, et al.. (2022). Progression and survival of MBL: a screening study of 10 139 individuals. Blood. 140(15). 1702–1709. 13 indexed citations

Wang, Zhiquan, Huihuang Yan, Justin C. Boysen, et al.. (2022). B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells. Blood Cancer Journal. 12(7). 99–99. 4 indexed citations

Ripoll, Juan G., Justin E. Juskewitch, Raymund R. Razonable, et al.. (2022). Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19. Blood Advances. 6(23). 5951–5955. 12 indexed citations

Maiti, Guru Prasad, Sutapa Sinha, Hasan Mahmud, et al.. (2021). SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. Blood Cancer Journal. 11(5). 93–93. 23 indexed citations

10.

Liebow, Mark, Melissa C. Larson, Carrie A. Thompson, et al.. (2021). Aspirin and other nonsteroidal anti‐inflammatory drugs, statins and risk of non‐Hodgkin lymphoma. International Journal of Cancer. 149(3). 535–545. 7 indexed citations

11.

Parikh, Sameer A., Sara J. Achenbach, Timothy G. Call, et al.. (2020). The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Medicine. 9(10). 3390–3399. 39 indexed citations

12.

Yan, Huihuang, Shulan Tian, Geffen Kleinstern, et al.. (2020). Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. Human Molecular Genetics. 29(16). 2761–2774. 5 indexed citations

13.

Mato, Anthony R., Chadi Nabhan, Neil E. Kay, et al.. (2017). Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clinical Lymphoma Myeloma & Leukemia. 18(2). 114–124.e2. 24 indexed citations

14.

Sinha, Sutapa, Justin C. Boysen, Charla Secreto, et al.. (2015). Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clinical Cancer Research. 21(9). 2115–2126. 59 indexed citations

15.

Tsukamoto, Shuntaro, Yuhui Huang, Motofumi Kumazoe, et al.. (2015). Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs. Molecular Cancer Therapeutics. 14(10). 2303–2312. 35 indexed citations

16.

Slager, Susan L., Sara J. Achenbach, Yan W. Asmann, et al.. (2013). Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes. Cancer Epidemiology Biomarkers & Prevention. 22(3). 461–466. 12 indexed citations

17.

Kelly, Jennifer L., Anne J. Novak, Zachary S. Fredericksen, et al.. (2010). Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma. Cancer Epidemiology Biomarkers & Prevention. 19(11). 2847–2858. 34 indexed citations

18.

Shanafelt, Tait D., Matthew T. Drake, Matthew J. Maurer, et al.. (2010). Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 117(5). 1492–1498. 104 indexed citations

19.

Tam, Constantine S., Tait D. Shanafelt, William G. Wierda, et al.. (2009). De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 114(5). 957–964. 114 indexed citations

20.

Ghosh, Asish K., Charla Secreto, Traci R. Knox, et al.. (2009). Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 115(9). 1755–1764. 189 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact